745 results about "Multipotential stem cell" patented technology

The present disclosure provides methods of differentiating pluripotent stem cells, including induced pluripotent stem cells, into lineage-specific floor plate midbrain progenitor cells, determined dopaminergic neuronal progenitor cells, committed dopaminergic neuronal progenitor cells and / or dopaminergic neuronal cells. Also provided are compositions uses thereof, such as for treating neurodegenerative diseases and conditions, including Parkinson's disease, and articles of manufacture and kits for use thereof.

The invention relates to a heart organoid and an in-vitro preparation method thereof, and belongs to the technical field of stem cells. The invention provides a heart organoid. The heart organoid is obtained by induced culture of an adherent pluripotent stem cell mass; the adherent pluripotent stem cell mass is obtained by adherent culture of a suspended pluripotent stem cell mass; the suspension pluripotent stem cell mass is obtained by suspension culture of pluripotent stem cells. According to the in-vitro preparation process of the heart organoid, after pluripotent stem cells form balls, the pluripotent stem cell balls are subjected to staged induced differentiation under adherent culture, so that cell subtypes such as epicardial cells and the like can be generated without additional addition or additional stimulation of signal channels, and the heart organoid is more homogeneous. The self-occurring multi-lineage coexisting heart organoid can better simulate biological events derived from multiple cell types and multiple cell subtypes in the early development process of an embryonic heart, and has great application prospects in exploration of pathogenic factors and potential treatment targets of congenital heart diseases.

The invention discloses for the first time pluripotent cells, including induced pluripotent stem cells, embryonic stem cells, hypo-immune pluripotent cells, cells that have been derived therefrom, and cells that have been biologically differentiated therefrom into particular tissue lineages that are ABO blood type O Rhesus Factor negative or otherwise evade rejection resulting from blood type antigen mismatch. The invention further provides universally acceptable “off-the-shelf” pluripotent cells and derivatives thereof for generating or regenerating specific tissues and organs.

The invention relates to a method of modulating the expression of an endogenous gene in a somatic cell derived from an induced pluripotent stem cell (iPSC), comprising differentiating an engineered iPSC capable of stable or inducible expression of a CRISPR-related protein into a somatic cell prior to introduction of a guide RNA (gRNA) sequence. The invention also relates to the engineered iPSC, cells obtained by the method and uses thereof.

The invention relates to the technical field of image processing, in particular to an induced pluripotent stem cell density detection method, computer equipment and a medium, and the method comprises the following steps: acquiring an induced pluripotent stem cell image; presetting a local area of each pixel point; obtaining a local brightness performance value according to the gray level distribution of the pixel points in the local area; obtaining local boundary ambiguity according to the gradient distribution characteristics; obtaining local form regularity according to the uniformity characteristic of gray level distribution in a pixel point local area; obtaining a density comprehensive performance value of each pixel point; clustering the pixel points to obtain a preset number of clusters; and respectively enhancing each cluster by adopting histogram equalization to obtain an enhanced induced pluripotent stem cell image, and carrying out density detection on the enhanced induced pluripotent stem cell image. The invention aims to enhance the induced pluripotent stem cell image and improve the accuracy of the cell density detection result.

The invention relates to a cochlea spiral neuron in-vitro organ as well as a construction method and application thereof, and provides a method for obtaining a mature inner ear neuron by utilizing human pluripotent stem cell differentiation in vitro and further constructing an inner ear neuron in-vitro organ on the basis of the mature inner ear neuron. The internal ear neuron in-vitro organoid function stage obtained by the method and the application thereof are also provided.

The invention provides construction and application of a human pluripotent stem cell-derived heart organoid traditional Chinese medicine extract toxicity test chip. The chip comprises a plurality of micro-cell culture chambers and a micro-fluidic pore channel, heart organoid culture is carried out in the micro-cell culture room, culture media are added in the micro-fluidic channel to maintain the activity of the heart organoid, and traditional Chinese medicine extracts are added to evaluate the toxicity of traditional Chinese medicine. By simulating the reaction of the heart organ, the toxicity of the traditional Chinese medicine can be evaluated, the safety and effectiveness information about the traditional Chinese medicine can be provided, finally, the use of experimental animals can be reduced, and the animal welfare can be improved.

The invention discloses a sheep formation state pluripotent stem cell culture medium and application thereof. The invention belongs to the technical field of biology, and particularly relates to a sheep formation state pluripotent stem cell culture medium and application thereof. The composition for culturing the sheep formation state pluripotent stem cells, disclosed by the invention, contains an N2B27 basic culture medium and cell factors, wherein the cell factors contain CHIR99021, IWR1, A419259, a recovery hub IL6, a recovery hub sIL6R, a recovery hub Activin A and a recovery hub FGF2 (Fibroblast Growth Factor 2). The culture medium prepared from the composition can obtain stable sfPSCs, and can be applied to construction of sheep gene editing model animals.

The problem addressed by the present invention is to provide a method for detecting undifferentiated pluripotent stem cells and a reagent for detection by measuring the amount of RNA expressed by MIR302CHG gene to enable detection of a small amount of remaining undifferentiated pluripotent stem cells.

In various aspects, the invention provides culture platforms, cell culture media, and methods of differentiating pluripotent cells into hematopoietic cells. In certain aspects, the invention also provides pluripotent stem cell-derived hematopoietic cells generated using the media and methods disclosed herein. The pluripotent stem cell-derived permanent HE cells produced by the methods provided herein are capable of differentiating into hematopoietic lineage cells comprising T cell progenitor cells and T cells in addition to NK cell progenitor cells, NK cells, NKT cells, or B cells.

The present invention relates to a modified pluripotent cell and to a method for forward programming said cell. The invention further relates to use of said modified pluripotent stem cell for tissue engineering and to a food product comprising said modified pluripotent stem cell.

The invention belongs to the technical field of stem cell development and differentiation, and discloses application of polypeptide DGEA or a derivative thereof in promoting pluripotent stem cells to be differentiated into mesenchymal stem cells. The invention specifically discloses application of the polypeptide and the derivative thereof in promoting differentiation of pluripotent stem cells into pluripotent stem cells or preparing products for promoting differentiation of pluripotent stem cells into pluripotent stem cells. The amino acid sequence of the polypeptide is DGEA. The invention discloses the application of DGEA in promoting differentiation of pluripotent stem cells (embryonic stem cells, embryonic germ cells or induced pluripotent stem cells) into pluripotent stem cells (mesenchymal stem cells) for the first time, and the effect of DGEA is verified through corresponding experiments. The DGEA can obviously improve the efficiency of differentiating the embryonic stem cells, the embryonic germ cells or the induced pluripotent stem cells into the mesenchymal stem cells, and the obtained mesenchymal stem cells are high in safety and high in differentiation capacity.

The present invention relates to a method of transiently inducing aging in stem cells or somatic cells derived from induced pluripotent stem cells (iPSCs) by forward programming, the method comprising introducing one or more aging-inducing factors into the cell or exposing the cell to one or more exogenous aging-inducing factors for a period of time, the one or more aging-inducing factors are then removed or reduced, such as before or after forward programming of the iPSC, resulting in a reversal of the one or more aging phenotypes in the cell. Also provided are artificially aged stem cells or somatic cells derived from iPSC by forward programming, and their use in methods of identifying genes or combinations of genes involved in aged phenotype reversal or non-aged phenotype maintenance in cells. Also provided are methods of identifying a gene or combination of genes involved in aging phenotype reversal or non-aging phenotype maintenance in a cell comprising introducing one or more aging-inducing factors into the cell or exposing the cell to one or more exogenous aging-inducing factors for a period of time, and measuring the aging phenotype of the cell. In particular, methods of identifying a gene or combination of genes involved in aging phenotype reversal or non-aging phenotype maintenance in a cell optionally include loss of function, inhibition, knockout, function acquisition, or combination screening. Also provided is a method of regenerating somatic cells comprising altering the expression and / or activity of one or more genes identified by the methods described herein.

The present invention relates to a method for preparing a mammalian vascular network or mature mammalian bone marrow organoid. Also provided is the use of the prepared vascular network or mammalian bone marrow organoid in the treatment of bone marrow-related diseases, in vitro generation of BMO or mammalian blood cells, as a model system for the pathogenesis of bone marrow-related diseases, and as a system for identifying and / or testing pharmaceutically effective compounds for the treatment or prevention of bone marrow-related diseases.

The present invention relates to a medium for porcine pluripotent stem cells and use thereof, specifically provides a medium comprising: a first component that is IWR-1-endo; a second component that is selected from WH-4-023 or A419259; and a third component that is selected from fibroblast growth factors. The medium is easy to support the establishment of stable porcine pluripotent stem cell lines, especially the porcine E8-10 pre-gastrulation epiblast stem cell lines (known as pgEpiSCs).

The present invention relates to a modified stem cell and an ex vivo method for preparing defined mature cells from genetic programming of said modified stem cell which can be carried out in absence of certain growth factors, as well as a kit allowing to transform stem cells, and the different uses of the mature cells, for example for in vitro drug screening and toxicology or as cultivated meat. The genetic programming involves a molecular switch between two mutually exclusive programs of stem cell expansion and differentiation. The invention may be used for stem cells or other progenitors cells of any type, from any eukaryotic organism, but finds particular application in pluripotent stem cells from humans and livestock animals.

The invention relates to the field of biological medicine. Specifically, the invention relates to a cell differentiation method based on cell dynamic image machine learning. More specifically, the present invention relates to a method and apparatus for assisting in obtaining differentiated target cells (e.g., myocardial cells) from starting cells, such as pluripotent stem cells (e.g., induced pluripotent stem cells), using machine learning of cell dynamic images.

Disclosed is a method for producing T cells, the method comprising: (1) culturing three-dimensional cell aggregate(s) comprising cells that can differentiate into T cells, and stromal cells that express Notch ligand(s) derived from pluripotent stem cells. Also disclosed are T cells obtained by the method, and a medicine comprising the T cells.

The invention relates to an N2B27 culture medium for inducing generation of bidirectional pluripotent stem cells, one of LY2090314, AS1842856 or CHIR99021 is added into an N2B27 basal culture medium, and the concentration of the CHIR99021 is 10 mu M. The invention also relates to a preparation method of the N2B27 culture medium. The weight of the LY2090314 is 10 nM, and the weight of the AS1842856 is 0.6 [mu] M. The invention also provides an application of the culture medium in induced production of bidirectional pluripotent stem cells. According to the invention, a novel stem cell culture condition for promoting co-expression of genes OCT4 and CDX2 by adding small molecules LY2090314 (LY), AS1842856 (AS) and CHIR99021 to inhibit signal channels of FOXO1 and GSK3 is screened out. The culture conditions are simple and convenient, the application range is wide, the cultured cells keep the characteristics of 16-32 cell stages of the embryos, and the development characteristics of the embryos can be efficiently reproduced. Under the condition of not depending on transcription factors, the screened bidirectional pluripotent stem cells (BPSCs) can promote efficient generation of TSC cells and establish a TSC cell line through independent differentiation of a serum culture medium or induced differentiation of a TSC culture medium. The obstacles between early embryo pedigree are broken, and the research on early embryo development is promoted.

Methods for differentiating pluripotent stem cells to neuroectoderm in dynamic suspension culture using small molecule or protein inhibitors of TGFβ / Activin / Nodal signaling and BMP signaling are provided. Also provided are methoc and protocols for differentiating pluripotent stem cells such as human embryonic stem cells first to neuroectoderm, then further to glial progenitor cells, and further to oligodendrocyte progenitor cells (OPCs), and compositions obtained thereby. The methods of the present disclosure reproducibly produce neuroectoderm progenitor cells by day 7 of the differentiation process, glial progenitor cells by day 21 of the differentiation process and OPCs by day 42 of the differentiation process.

The invention provides a preparation method and a kit for reprogramming induced pluripotent stem cells of PBMC (peripheral blood mononuclear cells), particularly provides PBMC reprogramming based on mRNA-LNP (peripheral blood mononuclear cells), and more particularly relates to a preparation method for reprogramming induced pluripotent stem cells of peripheral blood mononuclear cells. The preparation method comprises the following steps: preparing a nano liposome mRNA (messenger ribonucleic acid) cocktail-LNP; according to the method, the nano-liposome mRNA-LNP is used for inducing peripheral blood mononuclear cells to reprogram, so that reprogrammed induced pluripotent stem cells are obtained, and an iPSCs reprogramming technology which is low in cost, low in toxicity, efficient, stable, repeatable and safer is realized. The invention also provides a reprogramming kit and a preparation method of the induced pluripotent stem cells.

Provided are chemical inducers of pluripotency (CIP) which include glycogen synthase kinase inhibitors, TGFβ receptor inhibitors, cyclic AMP agonists and S-adenosylhomocysteine hydrolase (SAH) inhibitors or histone acetylators. A method of inducing pluripotency in a partially or completely differentiated cell by using such chemical inducers of pluripotency is also provided. The method includes: (i) contacting a cell with the CIPs for a sufficient period of time to result in reprograming the cell into a pluripotent stem cell having ESC-like characteristics (CiPSC). Isolated chemically induced pluripotent stem cells (CiPSCs) and their progeny, produced by inducing differentiation of the CiPSCs, can be used in a number of applications, including but not limited to cell therapy and tissue engineering.

Methods for generating human vascular leptomeningeal cells (VLMCs) from human oligodendrocyte progenitor cells (OPCs) are provided using chemically-defined culture media that allow for generation of differentiated cells in a 34-day culture protocol. Methods of generating human VLMCs from human pluripotent stem cells using chemically-defined culture media in a 40 day culture protocol are also provided. Culture media, isolated cell populations, and kits are also provided.

The present invention provides methods of producing in vitro derived neutrophils or macrophages in xenogen- and serum-free conditions from pluripotent stem cells and in vitro derived populations of neutrophils and macrophages. Methods of treatment using in vitro derived neutrophils or macrophages are also contemplated.

The invention provides cell culture conditions for culturing stem cells, including feeder-free conditions for generating and culturing human induced pluripotent stem cells (iPSCs). More particularly, the invention provides a culture platform that allows long-term culture of pluripotent cells in a feeder-free environment; reprogramming of cells in a feeder-free environment; single-cell dissociation of pluripotent cells; cell sorting of pluripotent cells; maintenance of an undifferentiated status; improved efficiency of reprogramming; and generation of a naïve pluripotent cell.

The present application discloses a method for inducing cells to gain characteristics of naïve stem cell state comprising culturing the cells in the presence of a MUC1* activator.

Disclosed are: a method for producing a cell population containing regulatory T cells, the method comprising (1) culturing a cell population containing pluripotent stem cell-derived CD4+ T cells in the presence of at least one substance selected from the group consisting of a CDK8 and / or CDK19 inhibitor, a TNFR2 agonist, an mTOR inhibitor, and a TGF-βR agonist; a cell population containing regulatory T cells obtained by the method; and a medicine containing the cell population containing regulatory T cells.

The present invention provides a method for producing a cartilage-like tissue from pluripotent stem cells, the method comprising a step for culturing pluripotent stem cells in a cartilage differentiation culture medium and a step for increasing the ascorbic acid concentration of the cartilage differentiation culture medium. The present invention also provides a method for regulating the hardness of induced cartilage-like tissue differentiated from pluripotent stem cells, the method comprising a step for culturing pluripotent stem cells in a cartilage differentiation culture medium and a step for increasing the ascorbic acid concentration of the cartilage differentiation culture medium.

The invention relates to application of miRNA (micro Ribonucleic Acid) in regulation and control of cell reprogramming. It is found for the first time that a mixture of three miRNAs of hsa-miR-647, hsa-miR-450b-5p and hsa-miR-875-5p can induce fibroblasts to be reprogrammed into induced pluripotent stem cells, the three miRNAs have a synergistic effect, the statistical number of positive iPSCs colonies under combined transfection is obviously increased, and the expression quantity of Oct4, Sox2, c-Myc and Klf4 transcription factors generated through induction is also obviously increased. The reprogramming effect of the mixture of the three miRNAs is further proved, and the mixture can be used for realizing reprogramming of somatic cells. Compared with compound-induced reprogramming, the method disclosed by the invention has the advantages that a large number of induced pluripotent stem cells can be rapidly and efficiently obtained through in-vitro induction, the reediting efficiency is far higher than that of a currently known reediting method in the prior art, and the method has a good commercial application prospect.